{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["175(2)"],"submitter":["Blobner J"],"funding":["Universitätsklinikum Erlangen"],"pubmed_abstract":["<h4>Background</h4>The 2021 WHO classification of CNS tumors allows flexibility in the grading of IDH-mutant astrocytic gliomas, leading to some ambiguity. Following the approval of vorasidenib for WHO grade 2 astrocytomas and oligodendrogliomas based on the positive Phase III INDIGO trial, identifying prognostic criteria to differentiate between grade 2 and grade 3 tumors has become increasingly important.<h4>Methods</h4>We retrospectively searched our institutional database for patients meeting the diagnostic criteria for IDH-mutant astrocytomas (grade 2 and 3) according to the WHO 2021 classification. Clinical, radiological and molecular data were collected; outcome was compared using log-rank analysis and prognostic markers were subsequently forwarded in a multivariate model.<h4>Result"],"journal":["Journal of neuro-oncology"],"pagination":["763-774"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12420753"],"repository":["biostudies-literature"],"pubmed_title":["Clinical and neuropathological criteria for distinguishing between IDH-mutant astrocytomas of WHO grade 2 and 3."],"pmcid":["PMC12420753"],"pubmed_authors":["Teske N","Ruf V","Ringel F","Thon N","Schoenecker S","Blobner J","Tonn JC","Weller J","Karschnia P","von Baumgarten L","Forbrig R","Albert NL","Harter PN"],"additional_accession":[]},"is_claimable":false,"name":"Clinical and neuropathological criteria for distinguishing between IDH-mutant astrocytomas of WHO grade 2 and 3.","description":"<h4>Background</h4>The 2021 WHO classification of CNS tumors allows flexibility in the grading of IDH-mutant astrocytic gliomas, leading to some ambiguity. Following the approval of vorasidenib for WHO grade 2 astrocytomas and oligodendrogliomas based on the positive Phase III INDIGO trial, identifying prognostic criteria to differentiate between grade 2 and grade 3 tumors has become increasingly important.<h4>Methods</h4>We retrospectively searched our institutional database for patients meeting the diagnostic criteria for IDH-mutant astrocytomas (grade 2 and 3) according to the WHO 2021 classification. Clinical, radiological and molecular data were collected; outcome was compared using log-rank analysis and prognostic markers were subsequently forwarded in a multivariate model.<h4>Result","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-06-01T13:55:51.805Z","creation":"2026-04-08T13:11:52.551Z"},"accession":"S-EPMC12420753","cross_references":{"pubmed":["40702387"],"doi":["10.1007/s11060-025-05173-z"]}}